NASDAQ:JAZZJazz Pharmaceuticals Competitors & Alternatives

Johnson & Johnson (NYSE:JNJ) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.

Insider & Institutional Ownership

68.5% of Johnson & Johnson shares are owned by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 0.3% of Johnson & Johnson shares are owned by insiders. Comparatively, 4.6% of Jazz Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Johnson & Johnson and Jazz Pharmaceuticals' top-line revenue, earnings per share and valuation.

Johnson & Johnson has higher revenue and earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Johnson & Johnson has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for Johnson & Johnson and Jazz Pharmaceuticals, as reported by MarketBeat.

Johnson & Johnson presently has a consensus price target of $163.8571, suggesting a potential upside of 14.60%. Jazz Pharmaceuticals has a consensus price target of $157.1765, suggesting a potential upside of 41.35%. Given Jazz Pharmaceuticals' higher probable upside, analysts plainly believe Jazz Pharmaceuticals is more favorable than Johnson & Johnson.

Profitability

This table compares Johnson & Johnson and Jazz Pharmaceuticals' net margins, return on equity and return on assets.

Merck & Co., Inc. (NYSE:MRK) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Volatility & Risk

Merck & Co., Inc. has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500.

Insider and Institutional Ownership

74.3% of Merck & Co., Inc. shares are held by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are held by institutional investors. 0.3% of Merck & Co., Inc. shares are held by insiders. Comparatively, 4.6% of Jazz Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Merck & Co., Inc. and Jazz Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Merck & Co., Inc. has higher revenue and earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Merck & Co., Inc. and Jazz Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Merck & Co., Inc. and Jazz Pharmaceuticals, as provided by MarketBeat.com.

Merck & Co., Inc. currently has a consensus price target of $94.1538, suggesting a potential upside of 18.31%. Jazz Pharmaceuticals has a consensus price target of $157.1765, suggesting a potential upside of 41.35%. Given Jazz Pharmaceuticals' higher possible upside, analysts plainly believe Jazz Pharmaceuticals is more favorable than Merck & Co., Inc..

Pfizer (NYSE:PFE) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

Insider & Institutional Ownership

70.3% of Pfizer shares are held by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are held by institutional investors. 0.1% of Pfizer shares are held by insiders. Comparatively, 4.6% of Jazz Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Pfizer and Jazz Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current recommendations for Pfizer and Jazz Pharmaceuticals, as provided by MarketBeat.

Pfizer presently has a consensus price target of $38.6083, suggesting a potential upside of 11.88%. Jazz Pharmaceuticals has a consensus price target of $157.1765, suggesting a potential upside of 41.35%. Given Jazz Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Jazz Pharmaceuticals is more favorable than Pfizer.

Risk and Volatility

Pfizer has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500.

Valuation and Earnings

This table compares Pfizer and Jazz Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Pfizer has higher revenue and earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Summary

Jazz Pharmaceuticals beats Pfizer on 9 of the 14 factors compared between the two stocks.

Eli Lilly And Co (NYSE:LLY) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, valuation, risk, analyst recommendations and earnings.

Earnings & Valuation

This table compares Eli Lilly And Co and Jazz Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Eli Lilly And Co has higher revenue and earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Eli Lilly And Co, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Eli Lilly And Co and Jazz Pharmaceuticals, as provided by MarketBeat.

Eli Lilly And Co presently has a consensus target price of $169.7273, indicating a potential upside of 1.70%. Jazz Pharmaceuticals has a consensus target price of $157.1765, indicating a potential upside of 41.35%. Given Jazz Pharmaceuticals' higher possible upside, analysts clearly believe Jazz Pharmaceuticals is more favorable than Eli Lilly And Co.

Profitability

This table compares Eli Lilly And Co and Jazz Pharmaceuticals' net margins, return on equity and return on assets.

Institutional and Insider Ownership

77.4% of Eli Lilly And Co shares are held by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are held by institutional investors. 0.1% of Eli Lilly And Co shares are held by insiders. Comparatively, 4.6% of Jazz Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

Eli Lilly And Co has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500.

Summary

Eli Lilly And Co beats Jazz Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

Jazz Pharmaceuticals (NASDAQ:JAZZ) and AbbVie (NYSE:ABBV) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Jazz Pharmaceuticals and AbbVie, as provided by MarketBeat.com.

Jazz Pharmaceuticals currently has a consensus target price of $157.1765, indicating a potential upside of 41.35%. AbbVie has a consensus target price of $106.80, indicating a potential upside of 7.87%. Given Jazz Pharmaceuticals' higher possible upside, equities analysts plainly believe Jazz Pharmaceuticals is more favorable than AbbVie.

Profitability

This table compares Jazz Pharmaceuticals and AbbVie's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Jazz Pharmaceuticals and AbbVie's gross revenue, earnings per share (EPS) and valuation.

AbbVie has higher revenue and earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Jazz Pharmaceuticals has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500.

Institutional & Insider Ownership

89.1% of Jazz Pharmaceuticals shares are held by institutional investors. Comparatively, 72.4% of AbbVie shares are held by institutional investors. 4.6% of Jazz Pharmaceuticals shares are held by insiders. Comparatively, 0.1% of AbbVie shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Bristol-Myers Squibb (NYSE:BMY) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, valuation and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Bristol-Myers Squibb and Jazz Pharmaceuticals, as provided by MarketBeat.

Bristol-Myers Squibb currently has a consensus price target of $68.1667, indicating a potential upside of 13.25%. Jazz Pharmaceuticals has a consensus price target of $157.1765, indicating a potential upside of 41.35%. Given Jazz Pharmaceuticals' higher possible upside, analysts clearly believe Jazz Pharmaceuticals is more favorable than Bristol-Myers Squibb.

Earnings & Valuation

This table compares Bristol-Myers Squibb and Jazz Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Bristol-Myers Squibb has higher revenue and earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Bristol-Myers Squibb, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Bristol-Myers Squibb and Jazz Pharmaceuticals' net margins, return on equity and return on assets.

Institutional & Insider Ownership

74.2% of Bristol-Myers Squibb shares are owned by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 0.1% of Bristol-Myers Squibb shares are owned by company insiders. Comparatively, 4.6% of Jazz Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility & Risk

Bristol-Myers Squibb has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500.

Summary

Jazz Pharmaceuticals beats Bristol-Myers Squibb on 8 of the 14 factors compared between the two stocks.